These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9868964)

  • 21. Refractory anemia with an excess of blasts developed into overt leukemia with leukothrombocytosis.
    Takahashi I; Togitani K; Yokoyama M; Aita T; Makihata K; Sunami K; Shiromoto M; Nakamura T; Kawada I; Nishimura M
    Intern Med; 1995 Jan; 34(1):28-31. PubMed ID: 7718975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
    Ogata K; Yokose N; Nomura T
    Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cytochemical note on nucleoli of granulocytic precursors and granulocytes in patients suffering from the refractory anemia with excess blasts (RAEB) of the myelodysplastic syndrome (MDS).
    Smetana K; Jirásková I; Malasková V; Cermák J
    Neoplasma; 2002; 49(1):5-9. PubMed ID: 12044061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.
    Font P; Loscertales J; Benavente C; Bermejo A; Callejas M; Garcia-Alonso L; Garcia-Marcilla A; Gil S; Lopez-Rubio M; Martin E; Muñoz C; Ricard P; Soto C; Balsalobre P; Villegas A
    Ann Hematol; 2013 Jan; 92(1):19-24. PubMed ID: 22948274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
    Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome.
    Cukrová V; Neuwirtová R; Dolezalová L; Belicková M; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
    Exp Hematol; 2009 Mar; 37(3):386-94. PubMed ID: 19136196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predominant autoantibody production by early human B cell precursors.
    Wardemann H; Yurasov S; Schaefer A; Young JW; Meffre E; Nussenzweig MC
    Science; 2003 Sep; 301(5638):1374-7. PubMed ID: 12920303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trilineage extramedullary myeloid cell tumor in myelodysplastic syndrome.
    Hancock JC; Prchal JT; Bennett JM; Listinsky CM
    Arch Pathol Lab Med; 1997 May; 121(5):520-3. PubMed ID: 9167610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of dysmyelopoiesis in cats: 34 cases (1996-2005).
    Weiss DJ
    J Am Vet Med Assoc; 2006 Mar; 228(6):893-7. PubMed ID: 16536701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Myelodysplastic syndrome associated with clonal proliferation of B lymphocytes].
    Rupniewska ZM; Roliński J; Siedlecki JA; Kulik J; Bieganowski P; Pieńkowska B; Rygier J; Rozynkowa D; Wach M
    Acta Haematol Pol; 1993; 24(1):57-64. PubMed ID: 8488738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surrogate light chain is required for central and peripheral B-cell tolerance and inhibits anti-DNA antibody production by marginal zone B cells.
    Ren W; Grimsholm O; Bernardi AI; Höök N; Stern A; Cavallini N; Mårtensson IL
    Eur J Immunol; 2015 Apr; 45(4):1228-37. PubMed ID: 25546233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody.
    Soligo D; Delia D; Oriani A; Cattoretti G; Orazi A; Bertolli V; Quirici N; Deliliers GL
    Leukemia; 1991 Dec; 5(12):1026-30. PubMed ID: 1723130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathological study of myelodysplastic syndrome].
    Ohnishi Y; Nemoto K
    Rinsho Ketsueki; 1986 Sep; 27(9):1773-9. PubMed ID: 3806986
    [No Abstract]   [Full Text] [Related]  

  • 35. [Patient with anemia, thrombopenia and slight leukocytosis].
    Clemm C; Wick M; Bartl R; Goebel M; Kolb HJ
    Internist (Berl); 1990 Jun; 31(6):423-6. PubMed ID: 2376485
    [No Abstract]   [Full Text] [Related]  

  • 36. Deficiency of lymphocyte lectin-dependent cytotoxicity in myelodysplastic syndromes.
    Fontana L; De Sanctis G; De Rossi G; Bottari V; Petti MC; Ensoli F; Pasqualetti D; Mandelli F
    Acta Haematol; 1989; 82(1):1-6. PubMed ID: 2505468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Haemosiderosis bulbi in a patient with myelodysplastic syndrome (MDS RAEB-1)].
    Lukenda A; Bujger Z; Bajer-Feketić A; Kica S; Petricek I
    Lijec Vjesn; 2010; 132(7-8):232-4. PubMed ID: 20857808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clarification of possible anemia].
    Uprichard J; Bain BJ
    Praxis (Bern 1994); 2009 Dec; 98(24):1453-5. PubMed ID: 19953471
    [No Abstract]   [Full Text] [Related]  

  • 39. Myelodysplastic syndrome with erythroid hypoplasia: a rare and distinct clincopathological entity--a report of two cases.
    Kumar V; Dash S
    Indian J Pathol Microbiol; 2005 Jan; 48(1):36-7. PubMed ID: 16758786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
    Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
    J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.